FIA
STLN

FNY Investment Advisers’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

FNY Investment Advisers’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,000
Closed -$20K – 1468
2025
Q3 		$20K Buy
6,000
+2,000
+50% +$6.85K 0.01% 686
2025
Q2 		$8K Buy
+4,000
New +$10K ﹤0.01% 696

Other funds holding STLN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FNY Investment Advisers's STLN Position: Q4 2025 in Review

FNY Investment Advisers sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2025, closing a stake of 6,000 shares — an estimated $20K sold.

FNY Investment Advisers first reported a position in STLN in Q2 2025 and held it in 2 quarters. The position peaked at $20K in Q3 2025. 117 funds tracked by Wall St. Rank hold STLN as of Q4 2025.

  • FNY Investment Advisers reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 6,000 Starling Oncology Institute, Inc. Common Stock shares in Q4 2025, an estimated $20K.
  • FNY Investment Advisers first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2025 and held it in 2 quarters.
  • FNY Investment Advisers's Starling Oncology Institute, Inc. Common Stock position peaked at $20K in Q3 2025.
  • 117 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2025.

Based on FNY Investment Advisers's 13F filing for Q4 2025, filed 16 Jan 2026.